Budesonide/glycopyrronium bromide/formoterol

Budesonide/glycopyrronium bromide/formoterol, sold under the brand name Breztri Aerosphere among others, is an inhalable fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD).[1][2] It contains budesonide, glycopyrronium bromide, and formoterol fumarate dihydrate.[1][2] It is inhaled.[1]

Budesonide/glycopyrronium bromide/formoterol
Combination of
BudesonideInhaled corticosteroid
Glycopyrronium bromideAnticholinergic muscarinic antagonist
FormoterolLong-acting β2 agonist
Clinical data
Trade namesBreztri Aerosphere, Trixeo Aerosphere
Other namesBudesonide/glycopyrrolate/formoterol fumarate
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
administration		By mouth (inhalation)
ATC code
Legal status
Legal status
Identifiers
KEGG

The most common side effects include oral candidiasis (a fungal infection of the mouth), upper respiratory tract infection, pneumonia, back pain, muscle spasms, influenza, urinary tract infection, cough, sinusitis and diarrhea.[1]

The combination was approved for medical use in the United States in July 2020,[3][4] and in the European Union in December 2020.[2]

Medical uses

Budesonide/glycopyrronium bromide/formoterol is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.[1][2]

Society and culture

On 15 October 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Trixeo Aerosphere (formoterol fumarate dihydrate/glycopyrronium bromide/budesonide), intended for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled.[5] Trixeo Aerosphere was approved for medical use in the European Union in December 2020.[2]

See also

References
  1. "Breztri- budesonide, glycopyrrolate, and formoterol fumarate aerosol, metered". DailyMed. 23 July 2020. Retrieved 15 September 2020.
  2. "Trixeo Aerosphere EPAR". European Medicines Agency (EMA). Retrieved 5 January 2021.
  3. "Breztri Aerosphere approved in the US for the maintenance treatment of COPD". AstraZeneca (Press release). 24 July 2020. Retrieved 15 September 2020.
  4. "Drugs@FDA: Breztri Aerosphere". U.S. Food and Drug Administration (FDA). Retrieved 15 September 2020.
  5. "Trixeo Aerosphere: Pending EC decision". European Medicines Agency (EMA). 16 October 2020. Retrieved 16 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.